In a phase I clinical trial, ascites-derived exosomes (Aex) in combination with the granulocyte-macrophage colony-stimulating factor (GM-CSF) were used in the immunotherapy of colorectal cancer (CRC). The gene discussed is CSF2; the disease is colorectal carcinoma.